New inhaled antibody could help asthma sufferers breathe easier

NCT ID NCT07589439

Recruiting now Disease control Sponsor: Shanghai Novamab Biopharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether an inhaled drug called LQ036 can improve lung function and asthma control in people whose asthma is not well managed with current treatments. About 216 participants will inhale the drug or a placebo once daily for 24 weeks. The main goal is to see if LQ036 increases the amount of air they can exhale in one second after 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LQ036 (a single-domain antibody given as a mist to inhale)
What this could lead to: If it works, this could offer a new daily inhaled treatment to help people with hard-to-control asthma breathe better and have fewer flare-ups.
What could go wrong: This is a mid-stage trial with only 216 people, so results may not apply to everyone. The drug is still experimental, and side effects or lack of benefit are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

Contacts and locations

Locations

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.